|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
BCR/ABL, p210 mRNA Detection by PCR
Test CodeBCRCML
Alias/See Also
BCR/ABL monitoring for CML
Preferred Specimen
4 mL EDTA whole blood
Minimum Volume
1 mL
Other Acceptable Specimens
1-3 mL Bone Marrow
Transport Container
EDTA tube
Transport Temperature
Ambient temperature
Specimen Stability
Must arrive at reference lab within 72 hours of collection
Report Available
4-7 days
Reference Range
An interpretive report will be provided.
Clinical Significance
Although various breakpoints within the BCR and ABL genes have been described, >95% of CMLs contain mRNA in which either the BCR exon 13 (e13) or BCR exon 14 (e14) is fused to the ABL exon 2 (a2), yielding fusion forms e13/a2 and e14/a2, respectively. The e13/a2 and e14/a2 fusion forms produce a 210-kDa protein (p210). The p210 fusion protein is an abnormal tyrosine kinase known to be critical for the clinical and pathologic features of CML, and agents that block the tyrosine kinase activity, such as imatinib, have been used successfully for treatment. It has been shown that monitoring the level of BCR/ABL mRNA (bcr/abl) in CML patients during treatment is helpful for both prognosis and management of therapy.(1-3)
